Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 10Unknown 9Recruiting 5Active not recruiting 3Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 438Carboplatin 322Nivolumab 286Cyclophosphamide 280Specimen Handling 257Cisplatin 252Paclitaxel 249Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 167atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 113Oxaliplatin 112Etoposide 111Radiosurgery 109venetoclax 108Fluorouracil 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Combined Modality Therapy × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04486911 2022-08-02

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

Shengjing Hospital

Phase 2 Active not recruiting
89 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡